Scientists Create Hybrid AI with Monkey Neurons
In a major breakthrough for biological computing, researchers have created a "pocket-sized AI brain" by integrating monkey neurons into an AI vision model. This hybrid approach reportedly shrank the model's physical size to 1/1000th of its original form, opening the door for ultra-efficient systems that combine biological and digital processing.
The Australian company Cortical Labs is a key player in this field, having launched the world's first commercial "biological computer," the CL1, in March 2025. Their approach, which they term Synthetic Biological Intelligence (SBI), aims to harness the superior energy efficiency and learning flexibility of biological neurons. This recent development builds on the company's 2022 "DishBrain" experiment, which gained international attention. In that study, researchers successfully taught a cluster of roughly 800,000 mouse and human brain cells grown on an electrode array to play a simplified version of the arcade game Pong. The system works by creating a closed feedback loop. Electrodes send signals to the neurons to represent information about a simulated world—for instance, the location of the ball in Pong—and then read the neurons' electrical responses to execute actions in that world. The neurons learn by trying to make their environment more predictable. While the initial Pong experiment was a two-dimensional task, more recent work has demonstrated organoids navigating the 3D environment of the video game Doom. This leap from a simple paddle game to a complex spatial environment shows a significant advance in the processing power of these bio-hybrid systems. A primary driver for this research is extreme energy efficiency. Biological brains consume a tiny fraction of the energy required by large-scale AI data centers, offering a potential solution to the massive and growing carbon footprint of modern artificial intelligence. Melbourne-based Cortical Labs was founded in 2019 and has raised $11.6 million over two funding rounds. Its latest Series A funding in April 2023 was led by Horizons Ventures, with participation from investors including Blackbird Ventures and In-Q-Tel. Immediate applications are focused on medical research and drug discovery. These systems allow scientists to test the effects of pharmaceutical compounds on functioning neural tissue, providing a more accurate and ethically superior alternative to animal testing for diseases like epilepsy and dementia.
